NZ619257A - Ketamine derivatives - Google Patents

Ketamine derivatives

Info

Publication number
NZ619257A
NZ619257A NZ619257A NZ61925712A NZ619257A NZ 619257 A NZ619257 A NZ 619257A NZ 619257 A NZ619257 A NZ 619257A NZ 61925712 A NZ61925712 A NZ 61925712A NZ 619257 A NZ619257 A NZ 619257A
Authority
NZ
New Zealand
Prior art keywords
oxocyclohexyl
chlorophenyl
amino
compounds
butanoate
Prior art date
Application number
NZ619257A
Inventor
James Wallace Sleigh
William Alexander Denny
Jiney Jose
Swarnalatha Akuratiya Gamage
Martyn Gregory Harvey
Logan James Voss
Original Assignee
Auckland Uniservices Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Auckland Uniservices Ltd filed Critical Auckland Uniservices Ltd
Priority to NZ619257A priority Critical patent/NZ619257A/en
Publication of NZ619257A publication Critical patent/NZ619257A/en

Links

Landscapes

  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

This disclosure relates to a family of compounds of formula (I). These are ketamine derivatives wherein Y1, Y2, X1 and X2 are as defined in the specification. The disclosure also related to pharmaceutical compositions comprising these compounds and methods of providing provide pain relief or analgesia and inducing and maintaining general anesthesia or sedation using these compounds. Examples of the compounds include: 3-((1-(2-chlorophenyl)-2-oxocyclohexyl)amino)propyl acetate, n-propyl 3-((1-(2-chlorophenyl)-2-oxocyclohexyl)amino)propanoate, ethyl4-((1-(2-chlorophenyl)-2-oxocyclohexyl)amino)butanoate, isopropyl 5-((1-(2-chlorophenyl)-2-oxocyclohexyl)amino)pentanoate and ethyl 4-((1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)amino)butanoate.
NZ619257A 2012-10-08 2012-10-08 Ketamine derivatives NZ619257A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ619257A NZ619257A (en) 2012-10-08 2012-10-08 Ketamine derivatives

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NZ619257A NZ619257A (en) 2012-10-08 2012-10-08 Ketamine derivatives

Publications (1)

Publication Number Publication Date
NZ619257A true NZ619257A (en) 2015-07-31

Family

ID=53773589

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ619257A NZ619257A (en) 2012-10-08 2012-10-08 Ketamine derivatives

Country Status (1)

Country Link
NZ (1) NZ619257A (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10869844B2 (en) 2014-09-15 2020-12-22 Janssen Pharmaceutica Nv Methods for the treatment of depression
US11446260B2 (en) 2013-03-15 2022-09-20 Janssen Pharmaceutica Nv Pharmaceutical composition of S-ketamine hydrochloride
US11707440B2 (en) 2017-12-22 2023-07-25 Janssen Pharmaceuticals, Inc. Esketamine for the treatment of depression
US11883526B2 (en) 2019-03-05 2024-01-30 Janssen Pharmaceutica Nv Esketamine for the treatment of depression
US11980596B2 (en) 2017-09-13 2024-05-14 Janssen Pharmaceutica Nv Delivery of esketamine for the treatment of depression

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11446260B2 (en) 2013-03-15 2022-09-20 Janssen Pharmaceutica Nv Pharmaceutical composition of S-ketamine hydrochloride
US10869844B2 (en) 2014-09-15 2020-12-22 Janssen Pharmaceutica Nv Methods for the treatment of depression
US11173134B2 (en) 2014-09-15 2021-11-16 Janssen Pharmaceutica Nv Methods for the treatment of depression
US11311500B2 (en) 2014-09-15 2022-04-26 Janssen Pharmaceutica Nv Methods for the treatment of depression
US11980596B2 (en) 2017-09-13 2024-05-14 Janssen Pharmaceutica Nv Delivery of esketamine for the treatment of depression
US11707440B2 (en) 2017-12-22 2023-07-25 Janssen Pharmaceuticals, Inc. Esketamine for the treatment of depression
US11883526B2 (en) 2019-03-05 2024-01-30 Janssen Pharmaceutica Nv Esketamine for the treatment of depression

Similar Documents

Publication Publication Date Title
MA32383B1 (en) Indazole derivatives with phenyl and benzodoxynil alternatives
IN2014MN02598A (en)
IL238327A0 (en) Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof and methods of use
EA201490228A1 (en) NEW DERIVATIVES OF TRIFTOROMETHYLOROXIAZOLE AND THEIR APPLICATION FOR THE TREATMENT OF DISEASE
TN2012000371A1 (en) Pyrazole compounds as crth2 antagonists
EA201300200A1 (en) N - ((6-AMINOPIRIDIN-3-IL) METHYL) HETEROARILKARBOXAMIDES AS KALLYCREIN INHIBITORS IN PLASMA
GEP20176631B (en) Alkoxy pyrazoles as soluble guanylate cyclase activators
MX2011012344A (en) Disaccharin, difumaric acid, di-l-hydroxy-2-naphthoic acid and mono-benzoic acid salts of 4- (dimethylamin0)butyl 2- (4- ( (2-amino-4-methyl-6- (pentylamino) pyrimidin- 5 -yl) methyl) phenyl)acetate.
IN2015DN01119A (en)
IN2014CN04530A (en)
IN2012DN03182A (en)
NZ619257A (en) Ketamine derivatives
GEP20186880B (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
MX2014004858A (en) Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated pathologies.
MY172729A (en) Pharmaceutical formulations
WO2013061004A8 (en) Novel disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases
EP2266626A4 (en) Composition for external application comprising transcription factor decoy as active ingredient
UA106532C2 (en) Pesticidal composition and its use
MX360330B (en) Administration regime for nitrocatechols.
IN2014DN02926A (en)
GB201305247D0 (en) Amide Compounds
MX2009010483A (en) 5-oxo-isoxazoles as inhibitors of lipases and phospholipases.
GEP201606566B (en) Isoxazolidine derivatives
EA201291401A1 (en) NEW ANTI-FIRING DERIVATIVES 5,6-DIHYDRO-4 - [(DIFTOROTHYL) PHENYL] -4H-PIRROLO [1,2-a] [1,4] BENZODIAZEPINA and 4- (DIFTORETHYL) PHENYL-6H-PIERR-RIR-6H-PIERR a] [1,4] BENZODIAZEPINA
WO2014166836A8 (en) Growth hormone compound formulation

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 DEC 2018 BY PATRIX IP SERVICES

Effective date: 20171025

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 DEC 2019 BY AJ PARK

Effective date: 20181112

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 DEC 2020 BY AJ PARK

Effective date: 20191112

LAPS Patent lapsed